Abstract 3231
Background
CT-guided percutaneous biopsy is a minimally invasive technique used for obtaining enough tissue samples in the diagnosis of pulmonary lesions. The common complications of CT-guided percutaneous lung biopsy include pneumothorax, hemoptysis. Coaxial technique makes it much easier to repeat sampling and obtain adequate specimens, still it makes no change to the high incidence of pneumothorax. Basic on the research De Filippoet al. had done about complications, we hypothesis that when the inner chuck of coaxial guiding needle was removed and the cutting needle was placed inside the guiding needle, the injection of a small amount of liquid (a mixture of lidocaine and hemocoagulase) through the syringe while withdraw of the guiding needle may help to prevent the incidence of pneumothorax for which close the needle track with liquid.
Methods
From August 24th, 2018 to April 1th ,2019, a total of 32 CT-guided percutaneous transthoracic biopsy procedures performed in 32 patients were retrospectively evaluated. The patients were divided into groups regarding the lesion from pleural surface: <30 mm or ≥ 30 mm. The rates of complications such as pneumothorax and pneumorrhagia were analyzed. And the complications were graded as mild/very mild, moderate, and severe. Different complications between the two groups were analyzed using Pearson’s Chi-squared test for categorical values.
Results
Pathology results were malignant in 28 patients (17 cases were adenocarcinoma), benign in 4 patients.7 cases (21.9%) happened pneumothorax (4 very mild pneumothorax, 2 mild pneumothorax, 1 moderate pneumothorax),13 cases (40.6%) happened pneumorrhagia (12 mild pneumorrhagia, 1 very mild pneumorrhagia). And there was no statistically significant between pneumothorax and the depth of lesion to pleural surface (P > 0.05).
Conclusions
Compared to co-axial technique only, CT-guided percutaneous lung biopsy using co-axial combined with "liquid withdraw" significantly reduced the incidence of pneumothorax, which has been confirmed what we found in earlier retrospective study. The new technique provided an more accurate, secure and reliable way to obtain adequate tissue samples in the diagnosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Comprehensive Cancer Center of Drum-Tower Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2607 - Single cycle induction treatment with Cisplatin/Docetaxel plus Durvalumab/Tremelimumab in Stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial)
Presenter: Markus Hecht
Session: Poster Display session 3
Resources:
Abstract
1388 - Radiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dillema finally resolved. An updated meta-analysis.
Presenter: Petar Suton
Session: Poster Display session 3
Resources:
Abstract
1478 - Treatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations.
Presenter: Majd Issa
Session: Poster Display session 3
Resources:
Abstract
3985 - Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Presenter: Jovian Yu
Session: Poster Display session 3
Resources:
Abstract
4036 - Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: study PANTERA
Presenter: Javier Martinez Trufero
Session: Poster Display session 3
Resources:
Abstract
4779 - Window of Opportunity for Durvalumab (MEDI4736) plus Metformin Trial in Squamous Cell Carcinoma of the Head and Neck (SCCHN): interim safety analysis
Presenter: Tony Richa
Session: Poster Display session 3
Resources:
Abstract
2757 - Severe Oral Mucositis (SOM) Mitigation by Genetically Modified Lactococcus Lactis Bacteria (LLB) Producing Human Trefoil Factor 1 (hTFF1; AG013) in Patients Being Treated With Concomitant Chemoradiation (CRT) for Oral and Oropharyngeal Cancers (OCOPC)
Presenter: Suraj Singh
Session: Poster Display session 3
Resources:
Abstract
5559 - Transcriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck
Presenter: Sanket Shukla
Session: Poster Display session 3
Resources:
Abstract
3263 - Risk and Impact of Renal Impairment of Locally Advanced Head and Neck Squamous Cell Carcinoma Patients Who Received Chemoradiotherapy with Cisplatin
Presenter: Thana Patimarattananan
Session: Poster Display session 3
Resources:
Abstract
3128 - Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
Presenter: Sumita Trivedi
Session: Poster Display session 3
Resources:
Abstract